Transdermal therapeutic system useful for treating, alleviating and/or preventing e.g. Parkinson's disease, depression, comprises backing layer, matrix layer comprising rotigotine, and protection film applied to part of matrix layer surface

Transdermal therapeutic system comprises: (i) a backing layer, (ii) a matrix layer comprising rotigotine, and (iii) a protection film, to be removed before use, which is applied to at least part of the surface of the matrix layer. The matrix layer is applied to at least part of the surface of the backing layer. The matrix layer further comprises an adhesive which is a styrene-butadiene block copolymer, and optionally at least one excipient. Independent claims are also included for: (1) a matrix for sustained release of rotigotine, adhesive comprising styrene-butadiene block copolymer, and optionally at least one additional excipient; (2) manufacturing the matrix for sustained-release of rotigotine comprising providing rotigotine, providing the adhesive comprising styrene-butadiene block copolymer, optionally providing excipients, and preparing matrix by mixing the components provided in previous with at least one solvent; and (3) producing a transdermal therapeutic system comprising providing rotigotine, providing the adhesive comprising styrene-butadiene block copolymer, optionally providing at least one excipient, preparing matrix by mixing the components provided in previous with at least one solvent, providing a protective film, and producing a two-layer active substance-containing laminate by coating at least a portion of the matrix to at least a part of the protective film, optionally subsequently drying the two-layer active substance-containing laminate under suitable drying conditions, providing a backing layer and producing a three-layer active substance-containing transdermal therapeutic system as the laminate by applying the protective film on at least a portion of the surface of the matrix layer of the two-layer laminate, and optionally dividing the three-layer active substance-containing laminate into at least two transdermal therapeutic systems. ACTIVITY : Antiparkinsonian; Antidepressant; Muscular-Gen; Neuroprotective; Analgesic. No biological data given. MECHANISM OF ACTION : None given. Die vorliegende Erfindung betrifft ein erfindungsgemäßes transdermales therapeutisches System (TTS) umfassend Rotigotin und ein pharmazeutisch akzeptables Klebemittel umfassend Styrol-Butadien-Block-Copolymer, eine erfindungsgemäße Matrix mit verzögerter Wirkstofffreisetzung von Rotigotin geeignet für ein TTS, ein erfindungsgemäßes Herstellverfahren für eine entsprechende Matrix oder ein entsprechendes TTS umfassend Rotigotin, sowie Verwendungen der erfindu